Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ribi Immunochem (ribi) -- Ignore unavailable to you. Want to Upgrade?

To: RMP who wrote (71)	4/5/1998 12:11:00 PM
From: JOHN KOLNIK	Respond to of 92

Ron, The Yahoo thread is fairly active. Go over there. go to Yahoo quotes enter ribi and then click on messages!! -- John

To: RMP who wrote (71)	4/29/1998 3:03:00 PM
From: Douglas Nordgren	Read Replies (1) \| Respond to of 92

NEWS: Ribi Reports Q1 1998 Sales Up 310% Over Q1 1997 biz.yahoo.com Wednesday April 29, 9:29 am Eastern Time Company Press Release SOURCE: Ribi ImmunoChem Research, Inc. HAMILTON, Mont., April 29 /PRNewswire/ -- A 310% increase in sales was reported today by Ribi ImmunoChem Research, Inc. (Nasdaq: RIBI - news) as part of the first quarter financial results for the period ending March 31, 1998. Sales for the quarter were $799,000 compared to $195,000 for the same period in 1997. Total revenues increased in the first quarter to $1,632,000, a 50% increase over total revenue of $1,087,000 for the same period last year. The increase in sales was due to the growing demand for Ribi adjuvants for infectious disease vaccines being developed by the Company's marketing partners. The net loss for the first quarter was $1,728,000 or $0.09 per share versus $1,663,000 or $0.08 per share for the comparable 1997 period. ''As Ribi and our marketing partners move closer to commercialization, we expect to see sales of our adjuvants increase to support supply and inventory requirements,'' said Robert E. Ivy, CEO, President and Chairman of Ribi ImmunoChem Research. ''We will also continue to incur costs associated with regulatory filings. This year the increase in revenue for the first quarter was offset by filing fees and costs associated with Ribi submissions to regulatory agencies reviewing Melacine melanoma theraccine for approval in Stage IV melanoma.'' Forward Looking Information Statements in this news release are based on current expectations. Actual results may differ materially based upon various risk factors. Additional information regarding risk factors is contained in the Company's Form 10-K for the year ended 1997, as filed with the U.S. Securities and Exchange Commission. Ribi ImmunoChem Research Inc. press releases are available through Company News On-Call by fax, 800-758-5804, ext. 752250, or at prnewswire.com.